Search
Zosuquidar
go.drugbank.com/drugs/DB06191InvestigationalZosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. … Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 2-RingN-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
go.drugbank.com/drugs/DB13948ExperimentalIt has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.
Categories: Serotonin 5-HT2 Receptor Agonists, Serotonin Receptor AgonistsSynonyms: N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineNOV-002
go.drugbank.com/drugs/DB05393InvestigationalNOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. … It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.
Etiprednol dicloacetate
go.drugbank.com/drugs/DB05442InvestigationalEtiprednol dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has been indicated in the treatment of asthma and Chron's disease.
LetibotulinumtoxinA
go.drugbank.com/drugs/DB16820Approved[L42330] LetibotulinumtoxinA has been a market-leading cosmetic product in South Korea for a number of years and was subsequently approved in the European Union. … [L42330] It is a 900 kDa multimeric complex comprising a 150 kDa toxin, a 130 kDa non-toxic non-haemagglutinating protein, and various other haemagglutinins.
Categories: Botulinum Toxins, Type ASynonyms: BoNT/A-DSVedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigationalVedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.
Categories: Integrin Receptor AntagonistProducts: ENTYVIO® 108 MG SOLUCIÓN INYECTABLE, ENTYVIO® (SUBCUTÁNEO) VEDOLIZUMAB 108 MG SOLUCIÓN INYECTABLELoteprednol etabonate
go.drugbank.com/drugs/DB14596ApprovedA number of such new formulations that have been approved include Kala Pharmaceutical's Inveltys - the first twice-daily (BID) ocular corticosteroid approved for this indication, designed specifically … Loteprednol Etabonate (LE) is a topical corticoid anti-inflammatory.
Mixtures: TOBRALOT 5 MG+3 MG/ML GÖZ DAMLASI, SÜSPANSİYON, 1 ADET, LOTEMICIN®Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLeuprolide
go.drugbank.com/drugs/DB00007ApprovedInvestigational[A203222] As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. … [L13850] Since this initial approval, various long-acting intramuscular and subcutaneous products have been developed such that patients can be dosed once every six months.
Categories: Gonadotropin Releasing Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor AgonistsInternational brands: Prostap 3Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective. … The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: REMLEAS™ hard capsules 40mgMotixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow … [L48141] It has also been investigated alongside [pembrolizumab] for the treatment of pancreatic cancer.[A261481]